title: Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.
abstract: BACKGROUND
  This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma.
  
  
  METHODS
  Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg/m2 on d 1 and d 8 and cisplatin 100 mg/m2 on day 1 every 4 weeks.
  
  
  RESULTS
  Thirty-seven patients were evaluable for response and 40 patients for tolerance. Twenty-four patients (64.8%) achieved objective responses. The median duration of response was 17.5 months (range 2.5-57 months), median time to progression was 13.2 months (range 0.4-57 months) and median survival was 20.6 months (range 0.4-55 months). This regimen was well-tolerated; no WHO grade 4 neutropenia was observed, grade 3 nausea and vomiting occured in 50% of patients and grade 2 peripheral neuropathy in 5% of patients.
  
  
  CONCLUSIONS
  Vinorelbine-cisplatin is an active and well-tolerated regimen in advanced cervical carcinoma.
authors.affiliation: National Hospital, Bloemfontein, South Africa.
authors.forename: Louis
authors.initials: L
authors.lastname: Goedhals
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Falkson
authors.forename: Brenda Lynn
authors.initials: BL
authors.lastname: Smith
authors.forename: Carla Isadora
authors.initials: CI
authors.lastname: Falkson
authors.forename: Jamal
authors.initials: J
authors.lastname: Gasmi
authors.forename: Andries
authors.initials: A
authors.lastname: Lategan
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Burillon
authors.forename: Patricia
authors.initials: P
authors.lastname: His
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine